publication date: Feb. 2, 2018

Conversation with the Cancer Letter Miller: “Doctors and patients have confidence in knowing that a test has gone through FDA” Vincent Miller

Vincent Miller

Chief medical officer of Foundation Medicine Inc

 

Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.

“I think doctors and patients have tremendous confidence in knowing that a test has gone through the scrutiny of FDA review,” Miller said to The Cancer Letter. “It offloads some of the thinking they need to do as they sit there with a patient and there are multiple issues on the table in a very short period of time to be addressed in which to see the patient.

“This becomes, I believe, indispensable to an important aspect of cancer care for patients with advanced or metastatic disease—selection of the most rational therapy.”

 

Miller spoke with Paul Goldberg, editor and publisher of The Cancer Letter.

 

Paul Goldberg:

First of all, what does this approval mean for the field of precision medicine?

Continue reading Miller: “Doctors and patients have confidence in knowing that a test has gone through FDA”

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.